Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6517900rdf:typepubmed:Citationlld:pubmed
pubmed-article:6517900lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0003483lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0033554lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0684321lld:lifeskim
pubmed-article:6517900lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:6517900pubmed:issue8-9lld:pubmed
pubmed-article:6517900pubmed:dateCreated1985-2-5lld:pubmed
pubmed-article:6517900pubmed:abstractTextThe effect of different prostaglandins on cell proliferation and intracellular lipid content in primary culture of human aortic cells has been studied. It was demonstrated that prostacyclin, its stable analogues (carbacyclin and 6 beta-PGI1), and prostaglandins E1, E2, D2 taken in the concentration of 0.5 micrograms/ml and 10 micrograms/ml decreased the 3H-thymidine uptake into cultured intimal smooth muscle cells by 2-3-fold. Carbacyclin and 6 beta-PGI1 also lowered by 1.5-2-fold the triglyceride and cholesteryl ester levels in cells cultured from atherosclerotic lesions. Prostaglandins E1, E2, D2 in the concentration of 10 micrograms/ml decreased by 20-40% total cholesterol level in cultured cells.lld:pubmed
pubmed-article:6517900pubmed:languageenglld:pubmed
pubmed-article:6517900pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6517900pubmed:citationSubsetIMlld:pubmed
pubmed-article:6517900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6517900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6517900pubmed:statusMEDLINElld:pubmed
pubmed-article:6517900pubmed:issn0232-766Xlld:pubmed
pubmed-article:6517900pubmed:authorpubmed-author:SmirnovV NVNlld:pubmed
pubmed-article:6517900pubmed:authorpubmed-author:OrekhovA NANlld:pubmed
pubmed-article:6517900pubmed:authorpubmed-author:TertovV VVVlld:pubmed
pubmed-article:6517900pubmed:authorpubmed-author:GelingN GNGlld:pubmed
pubmed-article:6517900pubmed:authorpubmed-author:KudryashovS...lld:pubmed
pubmed-article:6517900pubmed:issnTypePrintlld:pubmed
pubmed-article:6517900pubmed:volume43lld:pubmed
pubmed-article:6517900pubmed:ownerNLMlld:pubmed
pubmed-article:6517900pubmed:authorsCompleteYlld:pubmed
pubmed-article:6517900pubmed:paginationS284-6lld:pubmed
pubmed-article:6517900pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:meshHeadingpubmed-meshheading:6517900-...lld:pubmed
pubmed-article:6517900pubmed:year1984lld:pubmed
pubmed-article:6517900pubmed:articleTitleRegression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins.lld:pubmed
pubmed-article:6517900pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6517900lld:pubmed